# Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer

Source: https://onco.cc/trials/nct06949098/  
OnCo record `nct06949098` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Hebei Medical University Fourth Hospital, now recruiting.

## Summary

Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer is a phase 2, interventional study registered as NCT06949098 by Hebei Medical University Fourth Hospital, with a registry enrolment figure of 60 participants, started 2025-05-15 and due to reach its primary completion in 2032-03. Interventions recorded: Local Tumor Resection; Radiotherapy; Chemotherapy. Conditions listed: Rectal Cancer Stage I. Primary outcome: 5-year DFS Rate. Colorectal eligibility wording from the registry: "Biopsy-proven rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06949098
- Phase: 2
- Setting: An Exploratory Study of Local Resection Combined With Chemoradiotherapy in Patients With Low/Ultra-low Early-stage Rectal Cancer With a Strong Desire to Preserve the Anus
- Sponsor: Hebei Medical University Fourth Hospital
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06949098: https://clinicaltrials.gov/study/NCT06949098

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06949098.json